Cyclacel Pharmaceuticals Book Value 2011-2026 | CYCCP

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Cyclacel Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
6.84 M	-2.17 M	607 K	20.4 M	37.3 M	33.3 M	11.7 M	15.3 M	21.8 M	14.3 M	18.8 M	21.7 M	28 M	10 M	19.5 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
37.3 M	-2.17 M	17.2 M

Quarterly Book Value Cyclacel Pharmaceuticals

2025-Q3	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
7.1 M	3.06 M	-2.17 M	-970 K	999 K	-2.21 M	607 K	9.63 M	14.6 M	20 M	26.6 M	30.2 M	33.4 M	37.3 M	41.4 M	43.2 M	48 M	33.3 M	33.3 M	33.3 M	33.3 M	11.7 M	11.7 M	11.7 M	11.7 M	15.3 M	15.3 M	15.3 M	15.3 M	21.8 M	21.8 M	21.8 M	21.8 M	14.3 M	14.3 M	14.3 M	14.3 M	18.8 M	18.8 M	18.8 M	18.8 M	21.7 M	21.7 M	21.7 M	21.7 M	28 M	28 M	28 M	28 M	10 M	10 M	10 M	10 M	19.5 M	19.5 M	19.5 M	19.5 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
48 M	-2.21 M	19.1 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Midatech Pharma plc MTP	11.4 M	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Aptorum Group Limited APM	13.8 M	$ 0.89	-	$ 6.54 M	China
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	733 M	$ 22.35	0.68 %	$ 3.7 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Aeterna Zentaris AEZS	3.84 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
BioNTech SE BNTX	19.2 B	$ 103.69	2.08 %	$ 27.2 B	Germany
Brainstorm Cell Therapeutics BCLI	-9.98 M	-	-2.5 %	$ 5.88 M	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	69.4 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Innate Pharma S.A. IPHA	267 M	$ 1.48	-0.67 %	$ 235 M	France
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	169 M	-	-	$ 28.6 M	USA
AlloVir ALVR	78.8 M	-	4.14 %	$ 49.1 M	USA
Can-Fite BioPharma Ltd. CANF	20.3 M	$ 3.65	22.48 %	$ 6.01 M	Israel
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Applied Therapeutics APLT	-17.1 M	-	-	$ 8.42 M	USA
Aptose Biosciences APTO	-27.2 M	-	-45.71 %	$ 1.2 M	Canada
Aquestive Therapeutics AQST	-33.7 M	$ 4.08	0.74 %	$ 436 M	USA
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
Aridis Pharmaceuticals ARDS	-24.2 M	-	17.91 %	$ 11.1 M	USA
Arcutis Biotherapeutics ARQT	189 M	$ 22.65	1.25 %	$ 2.88 B	USA
Edesa Biotech EDSA	1.98 M	$ 16.23	2.08 %	$ 51.9 M	USA
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Athira Pharma ATHA	27.8 M	-	-	$ 269 M	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
Avenue Therapeutics ATXI	1.83 M	-	-52.27 %	$ 4.45 M	USA
Aileron Therapeutics ALRN	16.9 M	-	10.36 %	$ 9.8 M	USA
Autolus Therapeutics plc AUTL	178 M	$ 1.42	0.71 %	$ 378 M	Britain
AVROBIO AVRO	94.7 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	48.7 B	-	-	$ 96.9 B	Britain
Evogene Ltd. EVGN	12 M	$ 0.79	4.79 %	$ 27.9 M	Israel
Atreca BCEL	78.4 M	-	-11.76 %	$ 5.79 M	USA
BioDelivery Sciences International BDSI	188 M	-	-4.8 %	$ 255 M	USA
Exelixis EXEL	2.16 B	$ 45.0	0.69 %	$ 12.2 B	USA
BeiGene, Ltd. BGNE	4.36 B	-	0.49 %	$ 251 B	Cayman-islands
Завод ДИОД DIOD	-243 M	-	-	-	Russia